CD33 (Siglec-3) Inhibitory Function: Role in the NKG2D/DAP10 Activating Pathway
CD33 (siglec-3), a well-known target in leukemia therapy, is an inhibitory sialoadhesin expressed in human leukocytes of the myeloid lineage and some lymphoid subsets, including NK cells. It may constitute a control mechanism of the innate immune system; nevertheless, its role as an inhibitory recep...
Saved in:
| Main Authors: | Trinidad Hernández-Caselles, Rubén Corral-San Miguel, Antonio José Ruiz-Alcaraz, Pilar García-Peñarrubia |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2019/6032141 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
IL-12 drives the expression of the inhibitory receptor NKG2A on human tumor-reactive CD8 T cells
by: Olivier Fesneau, et al.
Published: (2024-11-01) -
Dåp i folkekyrkja
Published: (2021-01-01) -
Comprehensive Modular Synthesis of Ganglioside Glycans and Evaluation of their Binding Affinities to Siglec‐7 and Siglec‐9
by: Avijit K. Adak, et al.
Published: (2025-01-01) -
CD94-driven in vitro expansion of highly functional adaptive NKG2C+ NKG2A- CD57+ NK cells from CMV+ healthy donors
by: Chiara Giordano, et al.
Published: (2025-01-01) -
Effect of Hypoxia on Siglec-7 and Siglec-9 Receptors and Sialoglycan Ligands and Impact of Their Targeting on NK Cell Cytotoxicity
by: Husam Nawafleh, et al.
Published: (2024-10-01)